| Literature DB >> 35330882 |
Pan Peng1, Miriam Kessi1, Leilei Mao1, Fang He1, Ciliu Zhang1, Chen Chen1, Nan Pang1, Fei Yin1,2, Zou Pan1, Jing Peng1,2.
Abstract
Objective: To explore the etiology of infantile spasms (IS) in a large Chinese cohort based on the United States National Infantile Spasms Consortium (NISC) classification.Entities:
Keywords: etiologies; infantile spasms (IS); spectrum; variants; whole-exome sequencing (WES)
Year: 2022 PMID: 35330882 PMCID: PMC8940518 DOI: 10.3389/fped.2022.774828
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1The flow chart summarizing the steps involved in identifying the underlying etiology. Δ Tier1 laboratory investigations included complete blood count, glucose, electrolytes, urea, creatinine, AST, ALT, creatine kinase, ammonia, lactate, homocysteine, and ceruloplasmin. Ψ Brain MRI was rechecked after several months or cranial MRI thin slice scan/positron emission tomography-computed tomography (PET-CT) was performed on patients who had focal clinical seizures or focal abnormalities on EEG. ξ Further investigations included infectious or immunological tests, plasma amino acids, urine organic acids, karyotype analysis, chromosomal microarray analysis, customized multigene panel, whole-exome sequencing, and mitochondrial genome analysis. The performance of these investigations was based on neurologists' judgments of the probable etiology and varied among the patients. Forty-six patients refused any further investigations in this study. η There were 103 cases with available genetic data among those with a genetic disorder, while the remaining 17 met the clinical diagnostic criteria for tuberous sclerosis complex and 2 for neurofibromatosis.
The baseline characteristics of the group.
|
|
|
|
|---|---|---|
|
| ||
| Male | 330 | 61.0% |
| Female | 211 | 39.0% |
|
| ||
| Han | 514 | 95.0% |
| Non-Han | 27 | 5.0% |
|
| ||
| Early-onset, <3 m | 86 | 15.9% |
| Classic-onset, ≥3 to <12 m | 393 | 72.6% |
| Late-onset, ≥12 m | 62 | 11.5% |
|
| ||
| Yes | 133 | 24.6% |
| No | 408 | 75.4% |
|
| ||
| Yes | 161 | 29.8% |
| No | 380 | 70.2% |
|
| ||
| <32 w | 17 | 3.1% |
| ≥32 to <37 w | 33 | 6.1% |
| ≥37 w | 491 | 90.8% |
|
| ||
| <1,500 g | 10 | 1.9% |
| ≥1,500 to <2,500 g | 46 | 8.5% |
| ≥2,500 to <4,000 g | 461 | 85.2% |
| ≥4,000 g | 24 | 4.4% |
|
| ||
| Yes | 467 | 86.3% |
| No | 74 | 13.7% |
|
| ||
| Yes | 518 | 95.7% |
| No | 23 | 4.3% |
EEG, electroencephalograph; g, gram; m, month; w, week.
The specific causes of the group (N = 541).
|
|
|
|
|---|---|---|
| Structural-acquired ( | ||
| HIE with or without ICH/hypoglycemia | ||
| Perinatal insult | 62 | |
| Postnatal insult | 8 | |
| Intracranial infection | ||
| Bacterial meningitis (perinatal) | 9 (1) | |
| Viral meningoencephalitis | 8 | |
| Brain injury secondary to neonatal hypoglycemia | 18 | |
| ICH | ||
| Perinatal insult | 13 | |
| Postnatal insult | 3 | |
| Encephalomalacia with other causes | ||
| Indefinite perinatal insult | 2 | |
| CVM | 2 | |
| Incontinentia pigmenti | 1 | |
| Unknown causes | 8 | |
| Neuroglioma | 2 | |
| Focal brain lesion of unknown cause | 1 | |
| Genetic-structural ( | ||
| Tuberous sclerosis complex | ||
| | 4 | |
| | 10 | |
| NA | 17 | |
| Neurofibromatosis | ||
| | 2 | |
| NA | 2 | |
| 1 | ||
| 1 | ||
| 1 | ||
| 17p13.3 microdeletion (pachygyria-lissencephaly, heterotopia) | 1 | |
| Structural-congenital ( | ||
| Pachygyria-lissencephaly | 12 | |
| Focal cortical dysplasia | 4 | |
| Heterotopia | 2 | |
| Polymicrogyria | 1 | |
| Schizencephaly | 1 | |
| ≥2 Malformations | ||
| Pachygyria-lissencephaly, heterotopia, | 1 | |
| Heterotopia, focal cortical dysplasia, | 1 | |
| Heterotopia, agenesis of the corpus | 1 | |
| Focal cortical dysplasia, schizencephaly | 1 | |
| Intracranial hemangioma | 3 | |
| Genetic ( | ||
| 12 | ||
| 12 | ||
| 5 | ||
| 3 | ||
| 4 | ||
| 2 | ||
| 2 | ||
| 2 | ||
| 2 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| Xp22.13 microdeletion (harbors the exon 1 of the | 1 | |
| 20q13.33 microdeletion (harbors the | 1 | |
| 9q33.3-34.11 microdeletion (harbors the | 1 | |
| 9p24.3-22.3 microdeletion | 1 | |
| 5p12-11 microduplication (harbors the | 1 | |
| 3p25.3 microdeletion (harbors the | 1 | |
| 1p36.33 microdeletion (harbors the | 2 | |
| 1p36.33-32 microdeletion (harbors the | 1 | |
| Xp22.11-21.3 microduplication (harbors the | 1 | |
| 15q11.2 microduplication | 1 | |
| Metabolic ( | ||
| Disorder of glycosylation | ||
| | 2 | |
| | 1 | |
| | 1 | |
| Metal metabolism | ||
| Menkes disease ( | 1 | |
| Neurodegeneration with brain iron | 3 | |
| MMA ( | 1 | |
| Pyridoxine-dependent epilepsy ( | 1 | |
| SCAD deficiency ( | 1 | |
| Lysosomal storage diseases | ||
| | 1 | |
| Mitochondrial disorders ( | 1 | |
| Infection ( | ||
| Intra-uterine infection | 2 | |
| Unknown ( | ||
| Likely genetic | ||
| | 2 | |
| | 2 | |
| | 1 | |
| | 1 | |
| | 1 | |
| | 1 | |
| | 1 | |
| | 1 | |
| | 1 | |
| | 1 | |
| | 1 | |
| Likely metabolic (supporting evidence) | ||
| Pyridoxine-dependent epilepsy (resolved | 1 | |
| GLUT-1 deficiency syndrome | 1 | |
| Leukoencephalopathy (lesions in brain | 1 | |
| Hypophosphatasia ( | 1 | |
| Others | 236 |
CVM, cerebral venous malformation; GLUT, glucose transporter; HIE, hypoxic-ischemic encephalopathy; ICH, intracranial hemorrhage; MMA, methylmalonic academia; MRI, magnetic resonance imaging; NA, not applicable; SCAD, short-chain Acyl-CoA dehydrogenase.
Figure 2The distribution of the most common genes in the genetic IS group according to the ages of onset.